Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
暂无分享,去创建一个
[1] R. Hills,et al. The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome , 2011, Leukemia.
[2] Torsten Haferlach,et al. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Ko,et al. Do cancer centers need to assess quality and outcomes? Introducing a customized ACS-NSQIP for oncology (Onc-NSQIP). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] B. Löwenberg,et al. Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Dombret,et al. Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group , 2010 .
[6] R. Hills,et al. The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison , 2010 .
[7] E. Estey,et al. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. , 2010, Blood.
[8] J. Dipersio,et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Dombret,et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Sören Lehmann,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.
[11] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[12] R. Hills,et al. Low dose Ara-C versus low Dose Ara-C and Tipifarnib: result of the UK NCRI AML16 "Pick a Winner" comparison [Abstract] , 2008 .
[13] M. Parmar,et al. Speeding up the Evaluation of New Agents in Cancer , 2008, Journal of the National Cancer Institute.
[14] R. Hills,et al. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.
[15] Debra Speert,et al. Pick a winner , 2006 .
[16] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[17] Susan O'Brien,et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.
[18] Patrick Royston,et al. Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer , 2003, Statistics in medicine.
[19] C. Earle,et al. The outcomes and costs of acute myeloid leukemia among the elderly. , 2002, Archives of internal medicine.
[20] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[21] D J Sargent,et al. A flexible design for multiple armed screening trials , 2001, Statistics in medicine.